Skip to main content

Table 2 Antibodies, vendor, pretreatment, and dilution

From: Classification of patients with breast cancer according to Nottingham Prognostic Index highlights significant differences in immunohistochemical marker expression

Antibody

Clone

Source

Pretreatment

Dilution

ER

1D5

DAKO

pH 9.0

1:35

PR

636

DAKO

pH 9.0

1:50

HER-2

HercepTest

DAKO

pH 6.1

Ready to use

Ki-67

MIB-1

DAKO

pH 9.0

1:100

p53

DO-7

DAKO

pH 9.0

1:1000

Bcl-2

124

DAKO

pH 9.0

1:100